{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:27:28Z","timestamp":1789666048035,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Projects of Wuhan","award":["WX19Q30"],"award-info":[{"award-number":["WX19Q30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18832-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:10:28Z","timestamp":1759169428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["miR-340 reverses chemotherapy resistance in colon cancer via the PDCD4\/WNT\/\u03b2-catenin signalling pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Hanbing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"18832_CR1","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.3748\/wjg.v22.i30.6876","volume":"22","author":"T Hu","year":"2016","unstructured":"Hu, T., Li, Z., Gao, C. Y. & Cho, C. H. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J. Gastroenterol. 22, 6876\u20136889 (2016).","journal-title":"World J. Gastroenterol."},{"issue":"Suppl 3","key":"18832_CR2","doi-asserted-by":"publisher","first-page":"S312","DOI":"10.1016\/S0959-8049(11)70183-6","volume":"47","author":"A Stein","year":"2011","unstructured":"Stein, A., Atanackovic, D. & Bokemeyer, C. Current standards and new trends in the primary treatment of colorectal cancer. Eur. J. Cancer. 47(Suppl 3), S312\u2013S314 (2011).","journal-title":"Eur. J. Cancer."},{"key":"18832_CR3","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-08-2023","volume":"69","author":"NA Dallas","year":"2009","unstructured":"Dallas, N. A. et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 69, 1951\u20131957 (2009).","journal-title":"Cancer Res."},{"key":"18832_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","volume":"11","author":"R Krishna","year":"2000","unstructured":"Krishna, R. & Mayer, L. D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm Sci. 11, 265\u2013283 (2000).","journal-title":"Eur. J. Pharm Sci."},{"key":"18832_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","volume":"2","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48\u201358 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"18832_CR6","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369\u20137375 (2003).","journal-title":"Oncogene"},{"key":"18832_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1021\/ol902298s","volume":"12","author":"WS Li","year":"2010","unstructured":"Li, W. S. et al. Overcoming the drug resistance in breast cancer cells by rational design of efficient glutathione S-transferase inhibitors. Org. Lett. 12, 20\u201323 (2010).","journal-title":"Org. Lett."},{"key":"18832_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281\u2013297 (2004).","journal-title":"Cell"},{"key":"18832_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861\u2013874 (2011).","journal-title":"Nat. Rev. Genet."},{"issue":"9","key":"18832_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1517\/14728222.2013.819853","volume":"17","author":"L Hong","year":"2013","unstructured":"Hong, L. et al. MicroRNA-21: A therapeutic target for reversing drug resistance in cancer. Expert Opin. Ther. Targets 17(9), 1073\u20131080 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"18832_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2011.02.003","volume":"304","author":"J Li","year":"2011","unstructured":"Li, J., Chen, Y., Zhao, J., Kong, F. & Zhang, Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett. 304, 52\u201359 (2011).","journal-title":"Cancer Lett."},{"key":"18832_CR12","doi-asserted-by":"publisher","first-page":"153303382094580","DOI":"10.1177\/1533033820945801","volume":"19","author":"T Zhan","year":"2020","unstructured":"Zhan, T. et al. MiR-331-3p links to drug resistance of pancreatic cancer cells by activating WNT\/beta-Catenin signal via ST7L. Technol. Cancer Res. Treat 19, 1533033820945801 (2020).","journal-title":"Technol. Cancer Res. Treat"},{"key":"18832_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3892\/or.2015.4458","volume":"35","author":"K Huang","year":"2016","unstructured":"Huang, K., Tang, Y., He, L. & Dai, Y. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway. Oncol. Rep. 35, 887\u2013895 (2016).","journal-title":"Oncol. Rep."},{"key":"18832_CR14","first-page":"13108","volume":"8","author":"X Hou","year":"2015","unstructured":"Hou, X. & Qiao, H. Effect of miR-340 on gastric cancer cell proliferation and apoptosis. Int. J. Clin. Exp. Pathol. 8, 13108\u201313113 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"18832_CR15","first-page":"2875","volume":"21","author":"LL Zhang","year":"2017","unstructured":"Zhang, L. L. et al. miR-340 suppresses tumor growth and enhances chemosensitivity of colorectal cancer by targeting RLIP76. Eur. Rev. Med. Pharmacol. Sci. 21, 2875\u20132886 (2017).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"18832_CR16","doi-asserted-by":"publisher","first-page":"e12341","DOI":"10.1111\/cpr.12341","volume":"50","author":"H Zhou","year":"2017","unstructured":"Zhou, H. et al. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1\/P-gp expression. Cell Prolif. 50, e12341 (2017).","journal-title":"Cell Prolif."},{"key":"18832_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","volume":"6","author":"F Yu","year":"2021","unstructured":"Yu, F. et al. Wnt\/beta-catenin signaling in cancers and targeted therapies. Signal Transduct. Target Ther. 6, 307 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"18832_CR18","first-page":"982","volume":"23","author":"S Rongxin","year":"2019","unstructured":"Rongxin, S., Pengfei, L., Li, S., Xiaochen, J. & Yihe, H. MicroRNA-340-5p suppresses osteosarcoma development by down-regulating the Wnt\/beta-catenin signaling pathway via targeting the STAT3 gene. Eur. Rev. Med. Pharmacol. Sci. 23, 982\u2013991 (2019).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"18832_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/cas.12223","volume":"104","author":"DY Shen","year":"2013","unstructured":"Shen, D. Y., Zhang, W., Zeng, X. & Liu, C. Q. Inhibition of Wnt\/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci. 104, 1303\u20131308 (2013).","journal-title":"Cancer Sci."},{"issue":"7","key":"18832_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","volume":"26","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anticancer Drugs. 26(7), 706\u2013715 (2015).","journal-title":"Anticancer Drugs."},{"key":"18832_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7150\/ijbs.51123","volume":"17","author":"Z Huang","year":"2021","unstructured":"Huang, Z., Xu, Y., Wan, M., Zeng, X. & Wu, J. miR-340: A multifunctional role in human malignant diseases. Int. J. Biol. Sci. 17, 236\u2013246 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"18832_CR22","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1038\/onc.2012.311","volume":"32","author":"S Das","year":"2013","unstructured":"Das, S. et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene 32, 2927\u20132936 (2013).","journal-title":"Oncogene"},{"key":"18832_CR23","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.1038\/s41598-020-73792-9","volume":"10","author":"A Algaber","year":"2020","unstructured":"Algaber, A. et al. MicroRNA-340-5p inhibits colon cancer cell migration via targeting of RhoA. Sci. Rep. 10, 16934 (2020).","journal-title":"Sci. Rep."},{"issue":"2","key":"18832_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/ol.2021.12898","volume":"22","author":"A Algaber","year":"2021","unstructured":"Algaber, A., Madhi, R., Hawez, A., R\u00f6nnow, C. F. & Rahman, M. Targeting FHL2-E-cadherin axis by miR-340-5p attenuates colon cancer cell migration and invasion. Oncol. Lett. 22(2), 637 (2021).","journal-title":"Oncol. Lett."},{"key":"18832_CR25","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.18632\/oncotarget.23703","volume":"9","author":"R Arivazhagan","year":"2018","unstructured":"Arivazhagan, R. et al. MicroRNA-340 inhibits the proliferation and promotes the apoptosis of colon cancer cells by modulating REV3L. Oncotarget 9, 5155\u20135168 (2018).","journal-title":"Oncotarget"},{"key":"18832_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CAD.0000000000000614","volume":"29","author":"H Yan","year":"2018","unstructured":"Yan, H., Zhang, B., Fang, C. & Chen, L. miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1. Anticancer Drugs. 29, 440\u2013448 (2018).","journal-title":"Anticancer Drugs."},{"key":"18832_CR27","doi-asserted-by":"publisher","first-page":"10439","DOI":"10.7314\/APJCP.2014.15.23.10439","volume":"15","author":"L Shi","year":"2014","unstructured":"Shi, L. et al. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Asian Pac. J. Cancer Prev. 15, 10439\u201310444 (2014).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"18832_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"18832_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.biocel.2011.12.009","volume":"44","author":"D Fu","year":"2012","unstructured":"Fu, D. & Arias, I. M. Intracellular trafficking of P-glycoprotein. Int. J. Biochem. Cell Biol. 44, 461\u2013464 (2012).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"18832_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.20140","volume":"110","author":"K Klappe","year":"2004","unstructured":"Klappe, K., Hinrichs, J. W., Kroesen, B. J., Sietsma, H. & Kok, J. W. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int. J. Cancer. 110, 511\u2013522 (2004).","journal-title":"Int. J. Cancer."},{"key":"18832_CR31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"issue":"34","key":"18832_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202528","volume":"9","author":"CC Zheng","year":"2022","unstructured":"Zheng, C. C. et al. Blockade of nuclear \u03b2-catenin signaling via direct targeting of RanBP3 with NU2058 induces cell senescence to suppress colorectal tumorigenesis. Adv. Sci. (Weinh). 9(34), e2202528 (2022).","journal-title":"Adv. Sci. (Weinh)."},{"key":"18832_CR33","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.2147\/OTT.S253468","volume":"13","author":"H Chen","year":"2020","unstructured":"Chen, H., Pei, L., Xie, P. & Guo, G. Circ-PRKDC contributes to 5-fluorouracil resistance of colorectal cancer cells by regulating miR-375\/FOXM1 Axis and Wnt\/beta-catenin pathway. Onco Targets Ther. 13, 5939\u20135953 (2020).","journal-title":"Onco Targets Ther."},{"key":"18832_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/ijo.2016.3360","volume":"48","author":"X Wu","year":"2016","unstructured":"Wu, X., Luo, F., Li, J., Zhong, X. & Liu, K. Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway. Int. J. Oncol. 48, 1333\u20131340 (2016).","journal-title":"Int. J. Oncol."},{"key":"18832_CR35","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.4103\/0366-6999.238145","volume":"131","author":"SY Chen","year":"2018","unstructured":"Chen, S. Y., Du, Y. & Song, J. MicroRNA-340 inhibits epithelial-mesenchymal transition by impairing ROCK-1-dependent wnt\/beta-catenin signaling pathway in epithelial cells from human benign prostatic hyperplasia. Chin. Med. J. (Engl). 131, 2008\u20132012 (2018).","journal-title":"Chin. Med. J. (Engl)."},{"issue":"5","key":"18832_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3748\/wjg.v11.i5.726","volume":"11","author":"RF Chen","year":"2005","unstructured":"Chen, R. F., Li, Z. H., Kong, X. H. & Chen, J. S. Effect of mutated IkappaBalpha transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World J. Gastroenterol. 11(5), 726\u2013728 (2005).","journal-title":"World J. Gastroenterol."},{"key":"18832_CR37","doi-asserted-by":"publisher","first-page":"104650","DOI":"10.1016\/j.neuint.2019.104650","volume":"134","author":"Y Zheng","year":"2020","unstructured":"Zheng, Y. et al. MiR-340-5p alleviates oxygen-glucose deprivation\/reoxygenation-induced neuronal injury via PI3K\/Akt activation by targeting PDCD4. Neurochem. Int. 134, 104650 (2020).","journal-title":"Neurochem. Int."},{"issue":"6","key":"18832_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1159\/000508210","volume":"49","author":"W Zhou","year":"2020","unstructured":"Zhou, W., Huang, G., Ye, J., Jiang, J. & Xu, Q. Protective effect of miR-340-5p against brain injury after intracerebral hemorrhage by targeting PDCD4. Cerebrovasc. Dis. 49(6), 593\u2013600 (2020).","journal-title":"Cerebrovasc. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18832-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18832-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:10:29Z","timestamp":1759169429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18832-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18832"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18832-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33421"}}